

## TENDER NO. BMSIC/DRUGS/24-03

## Check list - I: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name :-Cotec Healthcare Pvt. Ltd.

Total Number of Pages Submitted in bid documents:- 1-121

| Sl. No | SBD clause serial No | Description of the Clause/ Technical Eligibility Criteria as per SBD as mentioned in the Check List                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Document/ fees submission status (Yes/ No) | Page number | Do the provided documents meet the eligibility criteria ? (Yes/ No) | Remarks                                                                                                                                       |
|--------|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|-------------|---------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| 1      | 3. (a)               | Tender Fee (Non-Refundable) of Rs 10,000/- + GST @18%, Total Rs 11,800 shall be submitted online (On E-Proc-2). This fee is payable only once for one tender irrespective of items contained therein.                                                                                                                                                                                                                                                                                                                                                                                            | Yes                                        | 24-25       | Yes                                                                 | —                                                                                                                                             |
| 2      | 3.(b)                | EMD shall be submitted ONLY in form of Bank Guarantee (Offline mode), drawn in favor of Managing Director, Bihar Medical Services and Infrastructure Corporation Limited from any Scheduled/Nationalized bank payable at Patna, as mentioned in Clause 2, as per following table:- S.N. No. of drugs quoted EMD Amount<br>1 Upto 5 drugs Rs1,00,000/- (One Lakh only)<br>2 For 6 to 10 Drugs Rs 2,00,000/- (Two Lakh only)<br>3 For 11 to 15 Drugs Rs 3,00,000/- (Three Lakh only)<br>4 For 16 to 20 Drugs Rs 4,00,000/- (Four Lakh only)<br>5 More than 20 Drugs Rs 5,00,000/- (Five Lakh only) | Yes                                        | 42-44       | Yes                                                                 | As Per Bid Document clause 3(b) BG Submitted for EMD must be schedule/Nationalized Bank Payable at Patna But firm has not submitted the same. |
| 3      | 3.(c)                | Documentary evidence of the constitution of the company/firm/Proprietorship such as Memorandum and Articles of Association, Partnership Deed etc. should be submitted with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor should be submitted.                                                                                                                                                                                                                                                      | Yes                                        | 27-39       | Yes                                                                 | —                                                                                                                                             |
| 4      | 3.(d)                | The details of Bidder Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.                                                                                                                                                                                                                                                                                                                                                                                                         | Yes                                        | 107         | Yes                                                                 | —                                                                                                                                             |
| 5      | 3.(e)                | Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm to sign the documents should be submitted.                                                                                                                                                                                                                                                                                                                                                                                                                                 | Yes                                        | 3-4         | Yes                                                                 | —                                                                                                                                             |
| 6      | 3.(l)                | Copies of the Audited Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than <b>25 Crores (Twenty-Five)</b> for any three of the last four consecutive financial years (Auditor/CA certificate of turnover will not be accepted). Self-attested copies are to be submitted.                                                                                                                                                                                                                                                                  | Yes                                        | 112-121     | Yes                                                                 | —                                                                                                                                             |
| 7      | 3.(m)                | Copy of Income Tax Return for any three of last four ConsecutiveAssessment years should be submitted (self-attested).                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Yes                                        | 61-63       | Yes                                                                 | —                                                                                                                                             |
| 8      | 3.(p)                | Copy of PAN Card of the bidder company should be submitted (self-attested).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Yes                                        | 49          | Yes                                                                 | —                                                                                                                                             |
| 9      | 3.(q)                | Copy of certificate of valid GST registration of the bidder company should be submitted (self-attested).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Yes                                        | 64-66       | Yes                                                                 | —                                                                                                                                             |

Anshu  
29/7/24

fy


## TENDER NO. BMSIC/DRUGS/24-03


## Check list - II: Evaluation sheet to be used for preliminary evaluation of technical bids


Company Name:- M/s Cotec Healthcare Pvt. Ltd. Total Number of Pages Submitted in bid documents:- 121

| Sl. No | SBD Clause serial No | Description of the Clause/ Technical Eligibility Criteria as per SBD, as mentioned in Check List                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Document/ fees submission status (Yes/ No) | Page Number as numbered by BMSICL | Do the provided documents meet the eligibility criteria ? (Yes/ No) | Remarks                                                                                |
|--------|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|-----------------------------------|---------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| 1      | 3.(d)                | The details of Bidder Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Yes                                        | 107                               | Yes                                                                 |                                                                                        |
| 2      | 3.(e)                | Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm to sign the documents should be submitted.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Yes                                        | 3-4                               | Yes                                                                 |                                                                                        |
| 3      | 3.(f)                | Minimum three years old valid Manufacturing License of the quoted product.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Yes                                        | 69-93                             | No                                                                  | For quoted product NIT sl. No. 38 product approval/product strength is not as per NIT. |
| 4      |                      | Manufacturing License along with approved product list must be valid till the last date of the submission of tender.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Yes                                        | 69-93                             | No                                                                  |                                                                                        |
| 5      |                      | Market standing certificate & Manufacturing certificate issued by the Licensing Authority as a Manufacturer for each drug quoted for the last 3 years (Certificate should be enclosed with list of items) except for the drugs falling under the category of 'New Drug' as defined by CDSCO (Central Drugs Standard Control Organisation). If permission in Form 46 from DCGI has been obtained, then the 3 years Manufacturing & Market standing clause will be relaxed. The provisions of Rule 122 E of Drugs and Cosmetics Act rule 1945 shall be applicable.<br><b>Explanation-</b> In case of Importers Permission in Form 45 from DCGI is required as Per Drugs & Cosmetics Act 1940 & Rules 1945. | Yes                                        | 18-22                             | Yes                                                                 |                                                                                        |
| 6      |                      | For all regulated products, the bidder should have at least two years of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCGI less than two years ago. A certificate from DCG (I) shall be required for all new regulated products to this effect.                                                                                                                                                                                                                                                                                     | NA                                         | NA                                | NA                                                                  |                                                                                        |


19/7/24


19/7/24


19/07/2024


19/07/24

|    |       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |     |         |     |                                                                                        |
|----|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|---------|-----|----------------------------------------------------------------------------------------|
| 7. |       | FFS (Flow Fill & Seal Process) Technology will be accepted wherever applicable.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | NA  | NA      | NA  |                                                                                        |
| 8  |       | Valid Pollution Control Clearance Certificate in accordance with Water [Prevention and control of Pollution] Act, 1974 & Air [Prevention and control of Pollution] Act, 1981 and Hazardous Wastes (Management, Handling & Trans Boundary Movement) Rules 2008 (Self Attested Copy of Certificate to be enclosed) (as applicable).                                                                                                                                                                                                                                                                                                                        | Yes | 100-106 | Yes |                                                                                        |
| 9  |       | Bidders shall submit self-attested copies of required manufacturing license and approved product list in support of above-mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it.                                                                                                                                                                                                                                                                                                                                                                                                     | Yes | 69-93   | No  | For quoted product NIT sl. No. 38 product approval/product strength is not as per NIT. |
| 10 | 3.(g) | In case of Importer, the bidder (importer) firm must have minimum three yearsold valid import License of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product is being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender.                                                                                                                                                                                                                            | NA  | NA      | NA  |                                                                                        |
| 11 | 3.(h) | Bidder must have Market Standing Certificate (in India) of minimum three years issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. Self-attested copies are to be submitted.                                                                                                                                                                                                                                                                                                                                                                                                                               | Yes | 18-22   | Yes |                                                                                        |
| 12 | 3.(i) | Non-Conviction Certificate (NCC) issued by the concerned Licensing Authority from Drugs Control Administration of the state for last three years should be submitted (wherever applicable). It should be not more than one year old. Self-attested copies are to be submitted.                                                                                                                                                                                                                                                                                                                                                                           | Yes | 09-11   | Yes |                                                                                        |
| 13 | 3.(j) | <b>WHO-GMP/GMP</b> (Good Manufacturing Practice) as per revised Schedule- 'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority/Drugs Control Department, (wherever applicable). The GMP certificate must not be older than one year from the date of publication of tender. Self-attested copies are to be submitted.<br><b>Explanation-</b> Generally the GMP Certificate is issued for one-year validity. Hence the provision that it should not be older than one year from the date of publication of tender implies mutatis mutandisthat the GMP certificate should remain valid till the date of submission of tender. | Yes | 50-55   | Yes |                                                                                        |
| 14 | 3.(k) | Maximum Production Capacity Certificate (Section wise) issued by concerned Licensing Authority from Drugs Control Department highlighting the quoted product section (wherever applicable). Self-attested copies are to be submitted. In case of Importer, an affidavit (with Stamp) sworn before first class magistrate/ Notary stating the batch production capacity of the firm and also that said production (Importing) capacity shall be adequate for requirement laid in NIT. Importer will have also to submit Invoices/evidence of import in items of said product with quantity details.                                                       | Yes | 12-14   | Yes |                                                                                        |

*Signature*  
19/7/24

*Signature*  
19/7/2024

*Signature*  
19/07/2024

*Signature*  
19/07/24

|    |                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |     |         |     |  |
|----|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|---------|-----|--|
| 15 | 3.(n)               | The tenderer should give an affidavit (with stamp) sworn before first class magistrate / Notary stating that the firm & its quoted product is not black listed / <b>Debarred currently</b> (as on the date of submission of the tender) by Central Government / Central Government agencies/any state government or any of the state government agencies / or any Drug procurement agencies or by BMSICL asper <b>Annexure-II</b> .                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Yes | 5-7     | Yes |  |
| 16 | 3. (o)              | List of items quoted in prescribed format as per <b>Annexure-III</b> duly signed.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Yes | 1-2     | Yes |  |
| 17 | 5.(k)               | An Affidavit (with stamp) regarding acceptance of tender conditions to be submitted by the bidding firm as per <b>Annexure-IV</b> .                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Yes | 59-60   | Yes |  |
| 18 | 5.(l)               | Filled check list as per given <b>Annexure-VI</b> to be submitted at the time of uploading the bid.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Yes | 110-111 | Yes |  |
| 19 | 7.(c)               | Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm should sign the documents in cases where person other than the Managing Director/Managing Partner or sole Proprietor signs the document.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Yes | 3-4     | Yes |  |
| 20 | 10.(c)              | If a particular document/Certificate to be uploaded as specified in bid, is not applicable for a bidder, the bidder shall attach a scanned copy of declaration in the letter head stating that the specific document is not applicable/exempted for the bidder in connection to this tender.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | NA  | NA      | NA  |  |
| 21 | 2(d)<br>Explanation | The price quoted by the bidders must not exceed the ceiling price as fixed by NPPA (National Pharmaceutical Pricing Authority) as per the provision of "Drugs Price Control Order" (wherever applicable) and the quoted rate should be at least 20% less than its MRP. In extraordinary cases the Managing Director, BMSICL has discretion to take decision.<br><b>Explanation-</b> In order to ensure procurement of the tendered drugs at the most appropriate and competitive rate, the bidders are directed to quote their lowest price as compared to the Rate provided to their respective Distributors/ Dealers/Wholesalers/ Carrying and Forwarding Agents/Authorized depot sales point in the State of Bihar. A Notarized affidavit to this effect on a Rs 100/- Non-judicial Stamp Paper should be submitted with the Bid in the prescribed format as mentioned in <b>Annexure-VIII</b> . | Yes | 108-109 | Yes |  |

*[Signature]*  
19/7/24

*[Signature]*  
19/7/2024

*[Signature]*  
19/07/2024

*[Signature]*  
19/07/24

## TENDER NO. BMSIC/DRUGS/24-03

Check list - III: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Cotec Healthcare Pvt. Ltd. Total Number of Pages Submitted in bid documents:- 121

Sheet to be used for verification of product approval and market standing

| Sl. No | NIT Sl. No | Name of the Quoted Drug           |                                                                | Pharmacopoeial Specification/ Strength    |                                                                                                                                                                              | Pack Size  |                 | Dosage Form          |                    | Approval Details |               |                                 | Last 3yrs market standing certificate/<br>New Drug |
|--------|------------|-----------------------------------|----------------------------------------------------------------|-------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------|----------------------|--------------------|------------------|---------------|---------------------------------|----------------------------------------------------|
|        |            | As per NIT                        | As per Approval                                                | As per NIT                                | As per Approval                                                                                                                                                              | As per NIT | As per Approval | As per NIT           | As per Approval    | Approval From    | Approved Upto | Approved in Brand /Generic Name |                                                    |
| 1      | 3          | Amikacin                          | Amikacin Sulphate injection IP 500mg<br>(page no. 82)          | 500 mg                                    | Each ml contains:<br>Amikacin Sulphate IP Eq to Amikacin 250mg preservative Methyl paraben IP 0.08% W/V Propyl paraben IP 0.02%W/V                                           | 2 ml Vial  | Not mentioned   | Injection            | Injection          | 03.01.2017       | 24.03.2025    | Generic                         | Submitted<br>(Page no. 21)                         |
| 2      | 5          | Amoxycillin + Potassium Clavunate | Amoxycillin and Potassium clavunate tablet IP<br>(page no. 83) | Amoxycillin 500 mg + Clavunic Acid 125 mg | Each film coated tablet contains:<br>Amoxycillin Trihydrate IP Eq to Amoxycillin 500mg potassium Clavunate diluted IP Eq to Clavunate acid 125mg Colour: Titanium Dioxide IP | 10x10      | Not mentioned   | Tablet               | Tablet             | 22.09.2017       | 24.03.2025    | Generic                         | Submitted<br>(Page no. 23)                         |
| 3      | 9          | Cefixime                          | Cefixime dispersible tablet IP 50mg<br>(page no. 84)           | 50mg (DT)                                 | Each uncoated dispersible tablet contains:<br>Cefixime IP anhydrous Cefixime 50 mg                                                                                           | 10 x 10    | Not mentioned   | Dispersible Tablet   | Dispersible Tablet | 12.04.2019       | 24.03.2025    | Generic                         | Submitted<br>(Page no. 23)                         |
| 4      | 10         | Cefotaxime                        | Cefotaxime Sodium 125 mg<br>(page no. 84)                      | 125 mg                                    | Each vial contains:<br>Sterile Cefotaxime Sodium IP Eq. to Cefotaxime 125 mg                                                                                                 | Vial       | Vial            | Injection            | Injection          | 12.04.2019       | 24.03.2025    | Generic                         | Submitted<br>(Page no. 23)                         |
| 5      | 11         | Ceftriaxone                       | Ceftriaxone Injection IP 250 mg                                | 250mg                                     | Each vial contains<br>Ceftriaxone Sodium IP Eq. to Ceftriaxone 250 mg                                                                                                        | Vial       | Vial            | Powder for Injection | Injection          | 24.04.2014       | 24.03.2025    | Generic                         | Submitted<br>(Page no. 23)                         |

*[Signature]*  
19/7/24

*[Signature]*  
19/7/2024

*[Signature]*  
19/07/2024

*[Signature]*  
19/07/24

|    |    |                                    |                                                   |            |                                                                                                                                                      |               |               |                         |            |            |            |         |                            |
|----|----|------------------------------------|---------------------------------------------------|------------|------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|---------------|-------------------------|------------|------------|------------|---------|----------------------------|
| 6  | 12 | Ceftriaxone                        | Ceftriaxone Injection IP 1000 mg<br>(page no. 85) | 1g         | Each vial contains:<br>Ceftriaxone sodium IP Eq. to<br>Ceftriaxone 1000 mg                                                                           | Vial          | Vial          | Powder for<br>Injection | Injection  | 24.04.2014 | 24.03.2025 | Generic | Submitted<br>(Page no. 23) |
| 7  | 24 | Lactulose                          | Lactulose Solution USP<br>(page no. 86)           | 10 g/15 ml | Each 5 ml contains:<br>Lactulose (Concentrated ) IP Eq. to<br>Lactulose 3.325g In a palatable<br>base q.s                                            | 100 ml bottle | Not mentioned | Oral liquid             |            | 10.02.2015 | 02.09.2026 | Generic | Submitted<br>(Page no. 19) |
| 8  | 29 | Meropenem                          | Meropenem Injection IP 500 mg<br>(page no. 87)    | 500mg      | Each vial contains:<br>Meropenem IP Eq. to anhydrous<br>Meropenem 500 mg                                                                             | Vial          | Vial          | Powder for<br>Injection | Injection  | 08.11.2019 | 24.03.2025 | Generic | Submitted<br>(Page no. 23) |
| 9  | 30 | Meropenem                          | Meropenem Injection IP<br>(page no. 88)           | 1g         | Each vial contains:<br>Meropenem IP (Sterile) Eq. to<br>anhydrous Meropenem 1000 mg<br>(Sodium as sodium carbonate)<br>90.2 mg                       | Vial          | Vial          | Powder for<br>Injection | Injection  | 29.09.2018 | 24.03.2025 | Generic | Submitted<br>(Page no. 23) |
| 10 | 34 | Ondansetron                        | Ondansetron Injection IP<br>(page no. 89)         | 2mg/ml     | Each ml contains:<br>Ondansetron hydrochloride IP Eq.<br>to Ondansetron 2 mg<br>Water for Injection IP q.s                                           | 2 ml Ampoule  | Not mentioned | Injection               | Injection  | 08.11.2019 | 24.03.2025 | Generic | Submitted<br>(Page no. 21) |
| 11 | 38 | Sodium chloride<br>(Normal Saline) | Saline Nasal Drops<br>(page no. 90)               | 0.9% w/v   | Sodium chloride IP 0.65% w/v<br>Benzalkonium chloride solution IP<br>0.03% w/v as preservative<br>(Product specification/strength<br>not as per NIT) | As Licensed   | Not mentioned | Nasal Drop              | Nasal Drop | 29.11.2017 | 24.03.2025 | Generic | Submitted<br>(Page no. 21) |



*[Signature]*  
19/7/24

*[Signature]*  
19/7/2024

*[Signature]*  
19/07/2024

*[Signature]*  
19/07/24

|    |    |                                                   |                                                               |          |                                                                                                                |                                                                                 |               |                       |                       |            |            |         |                            |
|----|----|---------------------------------------------------|---------------------------------------------------------------|----------|----------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|---------------|-----------------------|-----------------------|------------|------------|---------|----------------------------|
| 12 | 44 | Tranexamic acid                                   | Tranexamic acid Injection IP<br>(page no. 91)                 | 100mg/ml | Each ml contains:<br>Tranexamic acid IP 100 mg<br>water for Injection IP q.s                                   | 5ml Ampoule                                                                     | Not mentioned | Injection             | Injection             | 29.11.2017 | 24.03.2025 | Generic | Submitted<br>(Page no. 21) |
| 13 | 48 | Vitamin K1<br>(Phytomenadione<br>or Phyloquinone) | Phytomenadione Injection IP<br>(page no. 92)                  | 1 mg/ml  | Each ml contains;<br>Phytomenadione IP 1 mg<br>Water for Injection IP q.s                                      | 1 ml Ampoule                                                                    | Not mentioned | Injection             | Injection             | 13.10.2020 | 24.03.2025 | Generic | Submitted<br>(Page no. 21) |
| 14 | 49 | Zinc Sulphate                                     | Zinc Sulphate Dispersible tablet<br>IP 20 mg<br>(page no. 93) | 20mg     | Each uncoated Dispersible tablet<br>contains:<br>Zinc Sulphate (Monohydrate) IP<br>Eq. to Elemental Zinc 20 mg | 14 tablets should be<br>packed in<br>Aluminium -PVC<br>Blister 10<br>Strips/Box | Not mentioned | Dispersible<br>Tablet | Dispersible<br>Tablet | 01.02.2018 | 02.09.2026 | Generic | Submitted<br>(Page no. 19) |

 19/7/24
  19/7/2024
  19/07/2024
  19/07/24


## TENDER NO. BMSIC/DRUGS/24-03


Check list - IV: Evaluation sheet to be used for preliminary evaluation of technical bids


Company Name:- M/s Cotec Healthcare Pvt. Ltd. Total Number of Pages Submitted in bid documents:- 121


## Sheet for verification of licence details

| Sl. No. | NIT Sl. No | Name of the Drug as per NIT             | Manufacturer |                                | Importer     |                       | Validity   |            | GMP/ WHO GMP/ COPP (Import) |            |
|---------|------------|-----------------------------------------|--------------|--------------------------------|--------------|-----------------------|------------|------------|-----------------------------|------------|
|         |            |                                         | Forms Number | Manufacturing license Number   | Forms Number | Import license Number | From       | To         | From                        | To         |
| 1       | 3          | Amikacin                                | 28           | 41/UA/SC/P-2010<br>(Unit- II)  | NA           | NA                    | 26.03.2010 | 24.03.2025 | 02.01.2024                  | 01.01.2027 |
| 2       | 5          | Amoxycillin +<br>Potassium<br>Clavunate | 28           | 40/UA/SC/P-2010<br>(Unit- III) | NA           | NA                    | 26.03.2010 | 24.03.2025 | 02.01.2024                  | 01.01.2027 |
| 3       | 9          | Cefixime                                | 28           | 40/UA/SC/P-2010<br>(Unit- III) | NA           | NA                    | 25.03.2020 | 24.03.2025 | 02.01.2024                  | 01.01.2027 |
| 4       | 10         | Cefotaxime                              | 28           | 40/UA/SC/P-2010<br>(Unit- III) | NA           | NA                    | 25.03.2020 | 24.03.2025 | 02.01.2024                  | 01.01.2027 |
| 5       | 11         | Ceftriaxone                             | 28           | 40/UA/SC/P-2010<br>(Unit- III) | NA           | NA                    | 24.04.2014 | 24.03.2025 | 02.01.2024                  | 01.01.2027 |
| 6       | 12         | Ceftriaxone                             | 28           | 40/UA/SC/P-2010<br>(Unit- III) | NA           | NA                    | 24.04.2014 | 24.03.2025 | 02.01.2024                  | 01.01.2027 |


19/7/24


19/7/2024


19/07/2024


19/07/24

|    |    |                                                   |    |                                |    |    |            |            |            |            |
|----|----|---------------------------------------------------|----|--------------------------------|----|----|------------|------------|------------|------------|
| 7  | 24 | Lactulose                                         | 28 | 75/UA/SC/P-2006                | NA | NA | 10.02.2015 | 02.09.2026 | 02.01.2024 | 01.01.2027 |
| 8  | 29 | Meropenem                                         | 28 | 40/UA/SC/P-2010<br>(Unit- III) | NA | NA | 08.11.2019 | 24.03.2025 | 02.01.2024 | 01.01.2027 |
| 9  | 30 | Meropenem                                         | 28 | 40/UA/SC/P-2010<br>(Unit- III) | NA | NA | 29.09.2018 | 24.03.2025 | 02.01.2024 | 01.01.2027 |
| 10 | 34 | Ondansetron                                       | 28 | 40/UA/SC/P-2010<br>(Unit- III) | NA | NA | 26.03.2010 | 24.03.2025 | 02.01.2024 | 01.01.2027 |
| 11 | 38 | Sodium chloride<br>(Normal Saline)                | 28 | 40/UA/SC/P-2010<br>(Unit- III) | NA | NA | 26.03.2010 | 24.03.2025 | 02.01.2024 | 01.01.2027 |
| 12 | 44 | Tranexamic acid                                   | 28 | 40/UA/SC/P-2010<br>(Unit- III) | NA | NA | 26.03.2010 | 24.03.2025 | 02.01.2024 | 01.01.2027 |
| 13 | 48 | Vitamin K1<br>(Phytomenadione<br>or Phyloquinone) | 28 | 40/UA/SC/P-2010<br>(Unit- III) | NA | NA | 26.03.2010 | 24.03.2025 | 02.01.2024 | 01.01.2027 |
| 14 | 49 | Zinc Sulphate                                     | 25 | 76/UA/2006                     | NA | NA | 02.09.2006 | 02.09.2026 | 02.01.2024 | 01.01.2027 |

Note:- Assisted in technical evaluation in reference to letter no. BMSIC/40030/214-2024/3159 dt 10.07.2024 on the basis of documents provided by BMSICL as check list II, III & IV. Provided checklist compiled with due diligence and care. In spite, some inadvertent discrepancies could have been crept in. Humble request to all concerned to bring to the notice in due time if any discrepancies are observed for rectification.

*[Handwritten signatures and dates]*  
 19/7/24  
 19/7/2024  
 19/07/2024  
 19/07/24